About Emergent BioSolutions
Emergent BioSolutions is a company based in Gaithersburg (United States) founded in 1998.. The company has 900 employees as of December 31, 2024. Emergent BioSolutions has completed 5 acquisitions, including ADAPT Pharma, Cangene and PaxVax. Emergent BioSolutions operates in a competitive market with competitors including Vir Biotechnology, Vaxcyte, Cidara Therapeutics, Freeline and Valneva, among others.
- Headquarter Gaithersburg, United States
- Employees 900 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Emergent Biosolutions Inc.
-
Annual Revenue
$1.04 B-0.54as on Dec 31, 2024
-
Net Profit
$-190.6 M74.94as on Dec 31, 2024
-
EBITDA
$53.6 M0as on Dec 31, 2024
-
Latest Funding Round
$384.96 K (USD), Grant
Sep 01, 2022
-
Investors
HHS
& 5 more
-
Employee Count
900
as on Dec 31, 2024
-
Investments & Acquisitions
ADAPT Pharma
& 4 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Emergent BioSolutions
Emergent BioSolutions is a publicly listed company on the NYSE with ticker symbol EBS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Unlock access to complete
Unlock access to complete
Software Development Team
71 people
Leadership Team
60 people
Senior Team
23 people
Operations Team
19 people
Legal and Compliance
17 people
Finance and Accounting
15 people
Human Resources and Administration
13 people
Product Management Team
10 people
Unlock access to complete
Funding Insights of Emergent BioSolutions
- Total Funding Total Funding
- Total Rounds 17
- Last Round Grant — $384,958
-
First Round
First Round
(25 Jun 2008)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2022 | Amount | Grant - Emergent BioSolutions | Valuation |
investors |
|
| Apr, 2020 | Amount | Grant - Emergent BioSolutions | Valuation |
investors |
|
| Feb, 2020 | Amount | Post-IPO - Emergent BioSolutions | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Emergent BioSolutions
Emergent BioSolutions has secured backing from 6 investors, including institutional investors. Prominent investors backing the company include HHS, European Union and Public Health Emergency. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
Global firm uses systematic strategies and machine learning for investment returns.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Emergent BioSolutions
Emergent BioSolutions has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include ADAPT Pharma, Cangene and PaxVax. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapies for emergency conditions are developed and reformulated.
|
2014 | ||||
|
Oral vaccines against infectious diseases such as cholera, bird flu, HIV & others.
|
2007 | ||||
|
Antibody-like therapeutics for cancer and autoimmune diseases were developed.
|
1999 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Emergent BioSolutions
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Emergent Biosolutions Comparisons
Competitors of Emergent BioSolutions
Emergent BioSolutions operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Vir Biotechnology, Vaxcyte, Cidara Therapeutics, Freeline and Valneva, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of therapeutics for the treatment of infectious diseases
|
|
| domain | founded_year | HQ Location |
Vaccines for infectious diseases are developed using cell-free protein synthesis.
|
|
| domain | founded_year | HQ Location |
Novel anti-infectives for bacterial and fungal infections are developed.
|
|
| domain | founded_year | HQ Location |
Gene therapy platform is developed for chronic disease treatments.
|
|
| domain | founded_year | HQ Location |
Prophylactic vaccines for infectious diseases are developed and advanced.
|
|
| domain | founded_year | HQ Location |
Vaccines and immuno-biological drugs for infectious diseases are manufactured.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Emergent Biosolutions
Frequently Asked Questions about Emergent BioSolutions
When was Emergent BioSolutions founded?
Emergent BioSolutions was founded in 1998 and raised its 1st funding round 10 years after it was founded.
Where is Emergent BioSolutions located?
Emergent BioSolutions is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland, United States.
Who is the current CEO of Emergent BioSolutions?
Robert G Kramer is the current CEO of Emergent BioSolutions.
How many employees does Emergent BioSolutions have?
As of Dec 31, 2024, the latest employee count at Emergent BioSolutions is 900.
What is the annual revenue of Emergent BioSolutions?
Annual revenue of Emergent BioSolutions is $1.04B as on Dec 31, 2024.
What does Emergent BioSolutions do?
Founded in 1998 and headquartered in Gaithersburg, United States, Emergent BioSolutions operates in the biotechnology sector with a focus on vaccine development for infectious diseases. Key products include NuThrax, a combination anthrax vaccine, PreviThrax in phase 1 trials for anthrax, VAX161C for pandemic influenza, and UV-4B, an antiviral for dengue in early trials. Contract manufacturing services are also provided for bulk drug substances and sterile injectables.
Who are the top competitors of Emergent BioSolutions?
Emergent BioSolutions's top competitors include Vaxcyte, Serum Institute of India and Biological E.
Is Emergent BioSolutions publicly traded?
Yes, Emergent BioSolutions is publicly traded on NYSE under the ticker symbol EBS.
How many acquisitions has Emergent BioSolutions made?
Emergent BioSolutions has made 5 acquisitions, including ADAPT Pharma, Cangene, and PaxVax.
Who are Emergent BioSolutions's investors?
Emergent BioSolutions has 6 investors. Key investors include HHS, European Union, Public Health Emergency, Aigen Investment Management, and National Institute on Drug Abuse.
What is Emergent BioSolutions's ticker symbol?
The ticker symbol of Emergent BioSolutions is EBS on NYSE.